Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.

European urology - 1 Aug 2018

Ström Peter, Nordström Tobias, Aly Markus, Egevad Lars, Grönberg Henrik, Eklund Martin

Abstract excerpt

BACKGROUND: It has been shown that the Stockholm-3 model (S3M) outperforms prostate-specific antigen (PSA) as a screening tool for prostate cancer. OBJECTIVE: To update the S3M, to give a detailed account of the value of each predictor in the S3M, and to evaluate the S3M as a reflex test for men with PSA ≥3ng/ml. DESIGN, SETTING, AND PARTICIPANTS: During 2012-2015, the Stockholm-3 study evaluated the S3M relative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to Decision Support Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kallikreins

Share to Molecular Diagnostic Techniques

Share to Neoplasm Grading

Share to Prostate-Specific Antigen

Share to Prostatic Neoplasms

Share to Sweden

Source

Identifiers

PMID: 29331214
DOI: 10.1016/j.eururo.2017.12.028

Genes

HOXB13

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.PMID 29331214Read ↗

Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.Semantic proximity Read ↗

The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort.Semantic proximity Read ↗

Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.Semantic proximity Read ↗

Prostate cancer risk-stratification using proteomic estimation of KLK3 improves accuracy in screening applications: a population-based cohort study in the UK BiobankSemantic proximity Read ↗

The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients.Semantic proximity Read ↗

Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study.Semantic proximity Read ↗

KLK3 germline mutation I179T complements DNA repair genes for predicting prostate cancer progression.Semantic proximity Read ↗

Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3).Semantic proximity Read ↗

A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.Semantic proximity Read ↗

The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers.Semantic proximity Read ↗

A Urine-Based Exosomal Gene Expression Test Stratifies Risk of High-Grade Prostate Cancer in Men with Prior Negative Prostate Biopsy Undergoing Repeat BiopsySemantic proximity Read ↗

Improved prostate cancer prediction by combining Prostate-Specific Antigen (PSA) test results with Genetic Risk Scores (GRS/PRS)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.